NovaBay Pharmaceuticals, Inc. (NBY)
USD 0.49
(-0.45%)
USD 0.49
(-0.45%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -9.64 Million USD | 40.73% |
| 2022 | -16.26 Million USD | -147.98% |
| 2021 | -6.55 Million USD | 40.58% |
| 2020 | -11.03 Million USD | -5.26% |
| 2019 | -10.48 Million USD | -60.23% |
| 2018 | -6.54 Million USD | 11.59% |
| 2017 | -7.4 Million USD | 43.71% |
| 2016 | -13.15 Million USD | 30.69% |
| 2015 | -18.97 Million USD | -24.87% |
| 2014 | -15.19 Million USD | 5.29% |
| 2013 | -16.04 Million USD | -128.29% |
| 2012 | -7.02 Million USD | -38.19% |
| 2011 | -5.08 Million USD | -18.04% |
| 2010 | -4.3 Million USD | -259.73% |
| 2009 | 2.69 Million USD | 133.24% |
| 2008 | -8.11 Million USD | -50.26% |
| 2007 | -5.4 Million USD | -2.16% |
| 2006 | -5.28 Million USD | -52.64% |
| 2005 | -3.46 Million USD | -23.5% |
| 2004 | -2.8 Million USD | -187.0% |
| 2003 | -977 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -3.21 Million USD | 21.76% |
| 2024 Q2 | -1.58 Million USD | 50.68% |
| 2023 Q1 | -1.73 Million USD | 78.81% |
| 2023 FY | -9.64 Million USD | 40.73% |
| 2023 Q2 | -4.03 Million USD | -131.86% |
| 2023 Q3 | -1.75 Million USD | 56.42% |
| 2023 Q4 | -4.1 Million USD | -133.81% |
| 2022 Q4 | -8.2 Million USD | -41.65% |
| 2022 Q1 | -111 Thousand USD | 87.57% |
| 2022 FY | -16.26 Million USD | -147.98% |
| 2022 Q2 | -2.15 Million USD | -1841.44% |
| 2022 Q3 | -5.79 Million USD | -168.82% |
| 2021 Q4 | -893 Thousand USD | 60.99% |
| 2021 FY | -6.55 Million USD | 40.58% |
| 2021 Q1 | -1.51 Million USD | 13.45% |
| 2021 Q2 | -1.85 Million USD | -22.46% |
| 2021 Q3 | -2.28 Million USD | -23.13% |
| 2020 Q4 | -1.75 Million USD | 45.54% |
| 2020 Q1 | -1.58 Million USD | 54.62% |
| 2020 Q2 | -4.48 Million USD | -183.31% |
| 2020 FY | -11.03 Million USD | -5.26% |
| 2020 Q3 | -3.22 Million USD | 28.13% |
| 2019 Q2 | -2.53 Million USD | 39.6% |
| 2019 Q4 | -3.48 Million USD | -1136.17% |
| 2019 FY | -10.48 Million USD | -60.23% |
| 2019 Q1 | -4.18 Million USD | -230.36% |
| 2019 Q3 | -282 Thousand USD | 88.85% |
| 2018 Q2 | -1.58 Million USD | 26.09% |
| 2018 FY | -6.54 Million USD | 11.59% |
| 2018 Q3 | -1.53 Million USD | 3.21% |
| 2018 Q4 | -1.26 Million USD | 17.56% |
| 2018 Q1 | -2.15 Million USD | -371.12% |
| 2017 Q3 | -2.44 Million USD | -40.79% |
| 2017 Q2 | -1.73 Million USD | 56.67% |
| 2017 Q1 | -4.01 Million USD | -143.39% |
| 2017 FY | -7.4 Million USD | 43.71% |
| 2017 Q4 | 793 Thousand USD | 132.41% |
| 2016 Q1 | -5.07 Million USD | -20.77% |
| 2016 Q4 | -1.64 Million USD | 55.89% |
| 2016 FY | -13.15 Million USD | 30.69% |
| 2016 Q3 | -3.73 Million USD | -38.88% |
| 2016 Q2 | -2.69 Million USD | 47.02% |
| 2015 Q2 | -4.88 Million USD | -5.32% |
| 2015 Q4 | -4.2 Million USD | 19.8% |
| 2015 Q3 | -5.24 Million USD | -7.26% |
| 2015 FY | -18.97 Million USD | -24.87% |
| 2015 Q1 | -4.64 Million USD | -3.85% |
| 2014 Q4 | -4.46 Million USD | -5.9% |
| 2014 Q1 | -3.56 Million USD | 13.83% |
| 2014 FY | -15.19 Million USD | 5.29% |
| 2014 Q2 | -2.94 Million USD | 17.48% |
| 2014 Q3 | -4.21 Million USD | -43.41% |
| 2013 Q4 | -4.13 Million USD | -7.51% |
| 2013 Q2 | -4.04 Million USD | -0.97% |
| 2013 Q3 | -3.84 Million USD | 4.94% |
| 2013 FY | -16.04 Million USD | -128.29% |
| 2013 Q1 | -4 Million USD | -70.6% |
| 2012 Q4 | -2.35 Million USD | -3037.5% |
| 2012 FY | -7.02 Million USD | -38.19% |
| 2012 Q1 | -2.53 Million USD | 30.24% |
| 2012 Q2 | -2.22 Million USD | 12.05% |
| 2012 Q3 | 80 Thousand USD | 103.59% |
| 2011 Q4 | -3.62 Million USD | -3522.64% |
| 2011 Q2 | 425 Thousand USD | 121.38% |
| 2011 Q1 | -1.98 Million USD | -1334.78% |
| 2011 FY | -5.08 Million USD | -18.04% |
| 2011 Q3 | 106 Thousand USD | -75.06% |
| 2010 Q3 | -1.64 Million USD | -37.06% |
| 2010 Q4 | 161 Thousand USD | 109.81% |
| 2010 Q2 | -1.19 Million USD | 26.46% |
| 2010 Q1 | -1.62 Million USD | -147.7% |
| 2010 FY | -4.3 Million USD | -259.73% |
| 2009 Q3 | -111 Thousand USD | 61.59% |
| 2009 Q2 | -289 Thousand USD | 9.12% |
| 2009 Q1 | -318 Thousand USD | 79.3% |
| 2009 FY | 2.69 Million USD | 133.24% |
| 2009 Q4 | 3.41 Million USD | 3176.58% |
| 2008 Q1 | -2.67 Million USD | -92.11% |
| 2008 Q4 | -1.53 Million USD | -3.16% |
| 2008 Q3 | -1.48 Million USD | 38.22% |
| 2008 FY | -8.11 Million USD | -50.26% |
| 2008 Q2 | -2.41 Million USD | 10.01% |
| 2007 Q2 | -1.55 Million USD | -74.36% |
| 2007 Q1 | -893 Thousand USD | 25.65% |
| 2007 Q3 | -1.55 Million USD | 0.06% |
| 2007 Q4 | -1.39 Million USD | 10.41% |
| 2007 FY | -5.4 Million USD | -2.16% |
| 2006 Q3 | -1.37 Million USD | 7.97% |
| 2006 FY | -5.28 Million USD | -52.64% |
| 2006 Q2 | -1.49 Million USD | -22.58% |
| 2006 Q1 | -1.21 Million USD | -40.65% |
| 2006 Q4 | -1.2 Million USD | 12.59% |
| 2005 Q4 | -866 Thousand USD | 0.0% |
| 2005 Q2 | -866 Thousand USD | 0.0% |
| 2005 FY | -3.46 Million USD | -23.5% |
| 2005 Q3 | -866 Thousand USD | 0.0% |
| 2005 Q1 | -866 Thousand USD | 0.0% |
| 2004 FY | -2.8 Million USD | -187.0% |
| 2003 FY | -977 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -28.96 Million USD | 66.715% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -11.677% |
| Armata Pharmaceuticals, Inc. | -69.04 Million USD | 86.038% |
| Actinium Pharmaceuticals, Inc. | -48.81 Million USD | 80.253% |
| Azitra, Inc. | -11.28 Million USD | 14.568% |
| Can-Fite BioPharma Ltd. | -7.63 Million USD | -26.277% |
| Chromocell Therapeutics Corporation | -7.38 Million USD | -30.609% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | 67.004% |
| CEL-SCI Corporation | -32.36 Million USD | 70.216% |
| iBio, Inc. | -24.9 Million USD | 61.296% |
| Lineage Cell Therapeutics, Inc. | -21.48 Million USD | 55.134% |
| MAIA Biotechnology, Inc. | -19.77 Million USD | 51.246% |
| Matinas BioPharma Holdings, Inc. | -22.94 Million USD | 57.981% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | 36.483% |
| NanoViricides, Inc. | -8.29 Million USD | -16.227% |
| Oragenics, Inc. | -20.65 Million USD | 53.33% |
| BiomX Inc. | -26.16 Million USD | 63.163% |
| BiomX Inc. | -26.16 Million USD | 63.163% |
| Protalix BioTherapeutics, Inc. | 8.31 Million USD | 215.977% |
| Palatin Technologies, Inc. | -29.73 Million USD | 67.582% |
| Scorpius Holdings, Inc. | -45.21 Million USD | 78.681% |
| Theriva Biologics, Inc. | -18.34 Million USD | 47.463% |